{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:18:50Z","timestamp":1787797130106,"version":"build-2784847793"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00032\/2"],"award-info":[{"award-number":["MC_UU_00032\/2"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR207385"],"award-info":[{"award-number":["NIHR207385"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR200877"],"award-info":[{"award-number":["NIHR200877"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000883","name":"University of Bristol","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.vaccine.2026.128993","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:29:32Z","timestamp":1786638572000},"page":"128993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant"],"prefix":"10.1016","volume":"90","author":[{"given":"Fatema","family":"Kazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Yang","family":"Shapland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie P.","family":"Cornish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Henschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Cogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Sebastianski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Aarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma L.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Madley-Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Pelone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Petkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Probyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Saulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Savovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P.T.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128993_bb0005","unstructured":"WHO R&D Blueprint, \"COVID-19 vaccine tracker and landscape [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/teams\/blueprint\/covid-19\/covid-19-vaccine-tracker-and-landscape."},{"issue":"10","key":"10.1016\/j.vaccine.2026.128993_bb0010","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"\u201cProgress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape,\u201d (in eng)","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128993_bb0015","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2191577","article-title":"Tracking the COVID-19 vaccines: the global landscape","volume":"19","author":"Yadav","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128993_bb0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"\u201cCOVID-19 vaccines: rapid development, implications, challenges and future prospects,\u201d (in eng)","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"key":"10.1016\/j.vaccine.2026.128993_bb0025","doi-asserted-by":"crossref","unstructured":"B. Pratt and S. Bull, \"Equitable data sharing in epidemics and pandemics,\" BMC Med Ethics, vol. 22, no. 1, p. 136, 2021\/10\/06 2021, doi:https:\/\/doi.org\/10.1186\/s12910-021-00701-8.","DOI":"10.1186\/s12910-021-00701-8"},{"key":"10.1016\/j.vaccine.2026.128993_bb0030","article-title":"Challenges of data sharing in European COVID-19 projects: a learning opportunity for advancing pandemic preparedness and response","volume":"21","author":"Tacconelli","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2026.128993_bb0035","doi-asserted-by":"crossref","unstructured":"C. Watson, \"Rise of the preprint: how rapid data sharing during COVID-19 has changed science forever,\" Nat Med, vol. 28, no. 1, pp. 2\u20135, 2022\/01\/01 2022, doi:https:\/\/doi.org\/10.1038\/s41591-021-01654-6.","DOI":"10.1038\/s41591-021-01654-6"},{"key":"10.1016\/j.vaccine.2026.128993_bb0040","unstructured":"WHO, \"Landscape of observational studies on the effectiveness of COVID-19 vaccination [Internet]. [cited 2025 July 16].,\" Available from: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-observational-study-designs-on-the-effectiveness-of-covid-19-vaccination."},{"key":"10.1016\/j.vaccine.2026.128993_bb0045","unstructured":"WHO R&D Blueprint, \"WHO consultation on COVID-19 vaccines research - Advancing the development of pan-sarbecovirus vaccines. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/news-room\/events\/detail\/2022\/03\/25\/default-calendar\/save-the-date-who-consultation-on-covid-19-vaccines-research---advancing-the-development-of-pan-sarbecovirus-vaccines."},{"key":"10.1016\/j.vaccine.2026.128993_bb0050","unstructured":"WHO R&D Blueprint, \"Advancing the development of pan-sarbecovirus vaccines - Next steps [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/m\/item\/advancing-the-development-of-pan-sarbecovirus-vaccines---next-steps."},{"key":"10.1016\/j.vaccine.2026.128993_bb0055","unstructured":"WHO R&D Blueprint, \"COVID-19 new variants: Knowledge gaps and research [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/m\/item\/covid-19-new-variants-knowledge-gaps-and-research."},{"key":"10.1016\/j.vaccine.2026.128993_bb0060","unstructured":"WHO R&D Blueprint, \"WHO COVID-19 Vaccines Research: Can booster doses contribute to control this pandemic: what research is needed? [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/m\/item\/who-covid-19-vaccines-research-can-booster-doses-contribute-to-control-this-pandemic-what-research-is-needed."},{"key":"10.1016\/j.vaccine.2026.128993_bb0065","unstructured":"The COVID-NMA initiative, \"A living mapping and living systematic review of Covid-19 trials,\" Available at: https:\/\/covid-nma.com\/."},{"key":"10.1016\/j.vaccine.2026.128993_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.112071","article-title":"Including nonrandomized evidence in living systematic reviews: lessons learned from the COVID-NMA initiative","volume":"190","author":"Bonnet","year":"2026","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128993_bb0075","unstructured":"WHO R&D Blueprint, \"Prioritization of candidate vaccines for international support for further evaluation including Phase IIb\/3 randomized clinical trials [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/m\/item\/who-working-group-vaccine-prioritization-for-covid-19-vaccines."},{"key":"10.1016\/j.vaccine.2026.128993_bb0080","unstructured":"WHO R&D Blueprint, \"WHO Working Group \u2013 Vaccine R&D for COVID-19 Vaccines [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/m\/item\/who-working-group-vaccine-r-d-for-covid-19-vaccines."},{"issue":"10308","key":"10.1016\/j.vaccine.2026.128993_bb0085","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses (in eng)","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128993_bb0090","unstructured":"WHO, \"Immunization Analysis and Insights [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/immunization-analysis-and-insights\/surveillance\/covid-19-vaccine-effectiveness-and-impact."},{"key":"10.1016\/j.vaccine.2026.128993_bb0095","unstructured":"WHO, \"Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccine_effectiveness-VE_evaluations-2022.1."},{"key":"10.1016\/j.vaccine.2026.128993_bb0100","unstructured":"WHO, \"Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants: Interim guidance, 22 July 2021. Addendum to Evaluation of COVID-19 vaccine effectiveness [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccine_effectiveness-variants-2021.1."},{"key":"10.1016\/j.vaccine.2026.128993_bb0105","unstructured":"WHO, \"Evaluation of COVID-19 vaccine effectiveness [Internet]. [cited 2025 July 16],\" Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1."},{"key":"10.1016\/j.vaccine.2026.128993_bb0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128993_bb0115","unstructured":"C. C. Gra\u00f1a, A.;Boutron, I., A systematic review and network meta-analysis of vaccine for COVID-19. Available at: https:\/\/zenodo.org\/records\/6458272 (accessed 17 March 2026), 2021."},{"issue":"8","key":"10.1016\/j.vaccine.2026.128993_bb0120","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"W. H. O. W. G. o. t. C. Characterisation and C.-i. Management of","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128993_bb0125","unstructured":"VCiSB Team, \"Outbreak.info SARS-CoV-2 (hCoV-19) Mutation Reports,\" Available at: https:\/\/outbreak.info\/location-reports."},{"issue":"1","key":"10.1016\/j.vaccine.2026.128993_bb0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.2021.8565","article-title":"Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial","volume":"326","author":"Al Kaabi","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128993_bb0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128993_bb0140","article-title":"Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial","author":"Ella","year":"2021","journal-title":"medRxiv"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128993_bb0145","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"issue":"10275","key":"10.1016\/j.vaccine.2026.128993_bb0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2026.128993_bb0155","doi-asserted-by":"crossref","unstructured":"R. Palacios et al., \"Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study (April 11, 2021).\" Available at SSRN: https:\/\/ssrn.com\/abstract=3822780 or Doi: https:\/\/doi.org\/10.2139\/ssrn.3822780.","DOI":"10.2139\/ssrn.3822780"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128993_bb0160","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine (in eng)","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.vaccine.2026.128993_bb0165","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"10296","key":"10.1016\/j.vaccine.2026.128993_bb0170","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128993_bb0175","doi-asserted-by":"crossref","unstructured":"M. Voysey and A. J. Pollard, \"ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates &#x2013; Authors' reply,\" Lancet, vol. 397, no. 10291, p. 2248, 2021, doi:https:\/\/doi.org\/10.1016\/S0140-6736(21)00976-4.","DOI":"10.1016\/S0140-6736(21)00976-4"},{"key":"10.1016\/j.vaccine.2026.128993_bb0180","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128993_bb0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VI sualization (robvis): an R PACKAGE AND SHINY WEB APP FOR visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128993_bb0190","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128993_bb0195","doi-asserted-by":"crossref","unstructured":"W. Viechtbauer, \"Conducting Meta-analyses in R with the metafor package,\" J Stat Softw, vol. 36, no. 3, pp. 1\u201348, 08\/05 2010, doi:10.18637\/jss.v036.i03.","DOI":"10.18637\/jss.v036.i03"},{"key":"10.1016\/j.vaccine.2026.128993_bb0200","author":"R Core Team"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128993_bb0205","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4269\/ajtmh.22-0368","article-title":"COVID-19 vaccine effectiveness during a prison outbreak when omicron was the dominant circulating variant-Zambia, December 2021","volume":"107","author":"Simwanza","year":"2022","journal-title":"Am J Trop Med Hyg"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128993_bb0210","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/infdis\/jiac161","article-title":"Protection by vaccines and previous infection against the omicron variant of severe acute respiratory syndrome coronavirus 2","volume":"226","author":"Smid","year":"2022","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128993_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11020224","article-title":"A systematic review and Meta-analysis on the real-world effectiveness of COVID-19 vaccines against infection, symptomatic and severe COVID-19 disease caused by the omicron variant (B.1.1.529)","volume":"11","author":"Mohammed","year":"2023","journal-title":"Vaccines"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128993_bb0220","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2024.04.049","article-title":"A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants (in eng)","volume":"42","author":"Song","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128993_bb0225","doi-asserted-by":"crossref","unstructured":"J. DeCuir et al., \"Effectiveness of monovalent mRNA COVID-19 vaccination in preventing COVID-19-associated invasive mechanical ventilation and death among immunocompetent adults during the Omicron variant period - IVY network, 19 U.S. states, February 1, 2022-January 31, 2023,\" (in eng), MMWR Morb Mortal Wkly Rep, vol. 72, no. 17, pp. 463\u2013468, Apr 28 2023, doi:10.15585\/mmwr.mm7217a3.","DOI":"10.15585\/mmwr.mm7217a3"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128993_bb0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm7304a2","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128993_bb0235","doi-asserted-by":"crossref","unstructured":"D. Surie et al., \"Effectiveness of monovalent mRNA vaccines against COVID-19-associated hospitalization among immunocompetent adults during BA.1\/BA.2 and BA.4\/BA.5 predominant periods of SARS-CoV-2 omicron variant in the United States \u2013 IVY network, 18 states, December 26, 2021-august 31, 2022,\" (in eng), MMWR Morb Mortal Wkly Rep, vol. 71, no. 42, pp. 1327\u20131334, Oct 21 2022, doi:10.15585\/mmwr.mm7142a3.","DOI":"10.15585\/mmwr.mm7142a3"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128993_bb0240","doi-asserted-by":"crossref","first-page":"330","DOI":"10.15585\/mmwr.mm7315a2","article-title":"\u201cdurability of original monovalent mRNA vaccine effectiveness against COVID-19 omicron-associated hospitalization in children and adolescents - United States, 2021-2023,\u201d (in eng)","volume":"73","author":"Zambrano","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128993_bb0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2026.128993_bb0250","doi-asserted-by":"crossref","unstructured":"M. M. Higdon et al., \"A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease,\" Open Forum Infect Dis, vol. 9, no. 6, p. ofac138, Jun 2022, doi:https:\/\/doi.org\/10.1093\/ofid\/ofac138.","DOI":"10.1093\/ofid\/ofac138"},{"key":"10.1016\/j.vaccine.2026.128993_bb0255","doi-asserted-by":"crossref","unstructured":"W. Y. Au and P. P. Cheung, \"Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis [accepted 27 April 2022],\" BMJ, vol. 377, p. e069989, May 31 2022, doi:https:\/\/doi.org\/10.1136\/bmj-2022-069989.","DOI":"10.1136\/bmj-2022-069989"},{"key":"10.1016\/j.vaccine.2026.128993_bb0260","doi-asserted-by":"crossref","unstructured":"W. Y. Au and P. P. Cheung, \"Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis [accepted 15 November 2022],\" BMJ, vol. 377, p. e069989, Nov 2022 2022, doi:https:\/\/doi.org\/10.1136\/bmj-2022-069989.","DOI":"10.1136\/bmj-2022-069989"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128993_bb0265","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jval.2025.07.001","article-title":"Role of generative artificial intelligence in assisting systematic review process in health research: a systematic review","volume":"28","author":"Rashid","year":"2025","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2026.128993_bb0270","unstructured":"WHO, \"WHO issues updated guidance for strengthening health information systems,\" Available from: https:\/\/www.who.int\/europe\/news\/item\/11-06-2024-who-issues-updated-guidance-for-strengthening-health-information-systems."},{"key":"10.1016\/j.vaccine.2026.128993_bb0275","unstructured":"Israel Ministry of Health, \"Vaccines,\" Available from: https:\/\/www.gov.il\/en\/departments\/topics\/vaccines\/govil-landing-page."},{"key":"10.1016\/j.vaccine.2026.128993_bb0280","doi-asserted-by":"crossref","unstructured":"B. Rosen, N. Davidovitch, G. Chodick, and A. Israeli, \"The role of Israeli researchers in the scientific literature regarding COVID-19 vaccines,\" Israel J Health Policy Res, vol. 11, no. 1, p. 39, 2022\/11\/23 2022, doi:https:\/\/doi.org\/10.1186\/s13584-022-00548-3.","DOI":"10.1186\/s13584-022-00548-3"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128993_bb0285","doi-asserted-by":"crossref","first-page":"20155","DOI":"10.2807\/ese.17.17.20155-en","article-title":"The Danish vaccination register","volume":"17","author":"Grove Krause","year":"2012","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2026.128993_bb0290","unstructured":"D. V. Registry-SSI, Available from: https:\/\/en.ssi.dk\/."},{"key":"10.1016\/j.vaccine.2026.128993_bb0295","unstructured":"OpenSAFELY, Available from: https:\/\/www.opensafely.org\/research\/?utm_source=chatgpt.com."},{"issue":"13","key":"10.1016\/j.vaccine.2026.128993_bb0300","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.vaccine.2023.02.032","article-title":"A research and development (R&D) roadmap for broadly protective coronavirus vaccines: a pandemic preparedness strategy, (in eng)","volume":"41","author":"Moore","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128993_bb0305","unstructured":"PAHO, \"Guidance on conducting vaccine effectiveness evaluations in the setting of new SARS-CoV-2 variants: Interim guidance, 22 July 2021.,\" Available from: https:\/\/www.paho.org\/en\/documents\/guidance-conducting-vaccine-effectiveness-evaluations-setting-new-sars-cov-2-variants."},{"key":"10.1016\/j.vaccine.2026.128993_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100451","article-title":"\u201creported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: a systematic review and meta-regression analysis,\u201d (in eng)","volume":"17","author":"Nealon","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128993_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1195908","article-title":"Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies (in eng)","volume":"11","author":"Song","year":"2023","journal-title":"Front Public Health"},{"issue":"175","key":"10.1016\/j.vaccine.2026.128993_bb0320","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0222-2024","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024","volume":"34","author":"Zhou","year":"2025","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.vaccine.2026.128993_bb0325","unstructured":"UK Health Security Agency, \"100DM: how the UK is contributing to the global mission to develop pandemic-fighting tools within 100 days (Published 7 August 2023),\" Available from: https:\/\/www.gov.uk\/government\/publications\/100-days-mission-uk-specific-report-for-2022\/100dm-how-the-uk-is-contributing-to-the-global-mission-to-develop-pandemic-fighting-tools-within-100-days?utm_source=chatgpt.com."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26008029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:09:22Z","timestamp":1787796562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26008029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":65,"alternative-id":["S0264410X26008029"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128993","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128993"}}